NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the dosing of all the participants in a phase 3 trial of NurOwn (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The late-stage trial enrolled nearly 200 participants, who have been randomized […]
MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy of Cancer (SITC) annual conference to be held from November 6-10 in National Harbour, Maryland. Sorterra Cell Isolation System will separate white blood cells from human peripheral blood preserving sample […]
ProTom International has been given 510(k) clearance from the US Food and Drug Administration (FDA) for its Radiance 330 proton therapy system installed at the Massachusetts General Hospital (MGH) in Boston. According to the proton therapy technology manufacturer, the installed Radiance 330 proton therapy system is a compact, single-room system, which features an advanced pencil […]
Novartis has announced that the European Commission has expanded the approval of its multiple sclerosis drug, Gilenya (fingolimod), to include the treatment of children and adolescents aged 10 to 17 years with relapsing-remitting multiple sclerosis. This approval marks Gilenya as the first oral disease-modifying therapy authorized for this younger demographic in Europe. Pioneering oral therapy […]
Pfizer Inc., a leading US pharmaceutical company, has secured approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib), a groundbreaking treatment for anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC). This approval marks a significant milestone in the fight against a challenging form of cancer, particularly for patients whose […]